1/ 🚨New in Haematologica: Our team evaluated the impact of extramedullary disease (EMD) on toxicity and survival after BCMA CAR-T for multiple myeloma. EMD was associated with more severe toxicity and worse survival. 🧵Read on👇 🔗 haematologica.org/article/view/1…

Beautiful paper by my good friend Philipp Karschnia, amazing to see all your academic progress in the last decade! Highly recommended reading out in Nat Rev Neurology on all things CAR-T neurotoxicity - from ICANS to TIAN and MNTs👇

September 6 2025. Kraków welcome at the oldest polish Jagiellonian University 👍 All is free szpiczak2025.jordan.pl

MIDAS under the Microscope: Check out our special episode unpacking MIDAS trial in newly diagnosed #MultipleMyeloma with Meera Mohan! share.transistor.fm/s/93af17a0

A thoughtful and nuanced discussion on the results of MIDAS trial #mmsm #bmtsm Raj Chakraborty Eddie Cliff Meera Mohan podcasts.apple.com/us/podcast/blo…

Recs on prevention of infections during #CARTcell & bispecific antibody Tx in myeloma [6/7/23] Meera Mohan Raj Chakraborty Susan Bal Nellore Muhamed Baljević, MD, FACP @adsouza_md Peter G Pappas Jesus Berdeja, MD Elliothereum6391 Natalie Callander Luciano J Costa British Journal of Haematology doi.org/10.1111/bjh.18… #mmsm #IDonc

Effects of IVIG on Infections in Recipients of Teclistamab Tx for Multiple Myeloma: A Multi-Institutional Study [12/7/24] Cheruvalath et al. Meera Mohan #ASH24 Abst 256 ash.confex.com/ash/2024/webpr… #mmsm #IDonc #SuppOnc HT Rahul Banerjee, MD, FACP

🧵1/ Real-World Head-to-Head: Cilta-cel vs. Ide-cel in Myeloma 🧬 A prospective biomonitoring study (N=39) dives deep into the biologic and clinical differences between 2 BCMA CAR-Ts: cilta-cel and ide-cel. Results are eye-opening. #mmsm #MedEd #myeloma #MedTwitter #USMIRC

These woMMEn #myeloma doctors are exceptional physicians and outstanding individuals. They always say yes when I ask them to record a HealthTree University lesson. Consider supporting them in their fundraising endeavors. THANK YOU ladies. #mmsm give.healthtree.org/fundraiser/649…

🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 nature.com/articles/s4159… PDF: rdcu.be/ewqLH

Excellently written Nature Medicine review, and honestly the best graphics re: CAR-T toxicities (inc. infections & SPMs) that I’ve ever seen 👏 these will be used in slide decks everywhere! Congrats Kai Rejeski Joshua Hill, MD Michael Jain and thanks for writing this! #MMsm #lymsm

Check our recent work UAMS Myeloma Center published Blood Advances : Prognostic Impact of Focal Lesion Location and Persistence in Multiple Myeloma: Insights from Serial PET/DWI Imaging #mmsm ➡️ashpublications.org/bloodadvances/… n= 243 multiple myeloma patients followed 9.9 years with serial

#Myeloma Paper of the Day: Viewpoint piece makes evidence-based arguments for use of primary prophylaxis as a safer and simpler approach compared to preemptive IgG-guided immunoglobulin replacement therapy in pts getting bispecific antibodies: pubmed.ncbi.nlm.nih.gov/40690761/. #mmsm

Myeloma Paper of the Day, July 22nd, Suggested by Robert Orlowski (Robert Z. Orlowski) Rahul Banerjee, MD, FACP Meera Mohan Kai Rejeski Gurbakhash Kaur Nikita Mehra Noopur Raje oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM

Rewriting Risk: A Data-Driven Look at Myeloma Genetics | Journal of Clinical Oncology #mmsm #bmtsm Journal of Clinical Oncology Krina Patel ascopubs.org/doi/10.1200/JC…

OncoDaily Robert Z. Orlowski Meera Mohan Kai Rejeski Gurbakhash Kaur Nikita Mehra Noopur Raje Thank you for featuring this! Tweetorial below: x.com/RahulBanerjeeM…

Come work with us!! cc Madhav Dhodapkar Andrew Portuguese Danai Dima Richa Thakur, MD and many more not on Twitter!